Use of Parapox B2L protein to treat cancer and modify immune responses
AssigneeBayer Pharmaceuticals Corporation
InventorsDelanie Cassell, Jeffrey S. Tepper, Isa Samuels, Nathalie Dubois-Stringfellow
Life of this patent
Estimating the term…
Abstract
A purified Parapoxvirus ovis envelope protein termed “B2L” can be used as a monotherapeutic agent. B2L protein also can be used in screening methods to identify potential therapeutic agents for modulating a subject's immune response to the B2L protein.
Claims26
A method of enhancing an immune response to endogenous antigens, comprising the steps of:
- administering to a subject in need thereof an effective amount of a B2L viral envelope protein of a Parapox virus, whereby the B2L viral envelope protein enhances the immune response to endogenous antigens.
A method of treating a patient having a cell proliferative disorder, comprising the step of:
- administering to the patient an effective amount of a B2L viral envelope protein of a Parapox virus, whereby symptoms of the patient's cell proliferative disorder are ameliorated.
A method of eliciting in a patient an immune or inflammatory response to B2L protein, comprising the step of:
- administering to the patient an effective amount of a B2L viral envelope protein of a Parapox virus, whereby an immune or inflammatory response is generated.
A pharmaceutical composition comprising:
- a B2L viral envelope protein of a Parapox virus
A pharmaceutical composition comprising:
- a nucleic acid molecule encoding a B2L viral envelope protein of a Parapox virus
A method of identifying test compounds with the ability to modify a subject's immune and/or inflammatory response to B2L protein, comprising the steps of:
- contacting a dendritic cell in vitro with a sufficient amount of a purified B2L protein to observe a chemotactic effect of the B2L protein on the dendritic cell;
- and
- contacting the dendritic cell with the test compound, whereby a test compound that enhances the chemotactic effect of the B2L protein on the dendritic cell is identified as a potential agent for enhancing the subject's immune and/or inflammatory response to the B2L protein and whereby a test compound that decreases the chemotactic effect of the B2L protein on the dendritic cell is identified as a potential agent for inhibiting the subject's immune and/or inflammatory response to the B2L protein.
A method of identifying a test compound with the ability to modify a subject's immune and/or inflammatory response to B2L protein, comprising the steps of:
- contacting a purified B2L protein in vitro with a test compound;
- and
- determining whether the test compound and the B2L protein form a complex, whereby a test compound that forms a complex with the B2L protein is identified as a potential agent for modifying the subject's immune and/or inflammatory response to B2L protein.
A method of identifying test compounds with the ability to modify a subject's immune and/or inflammatory response to B2L protein, comprising the steps of:
- contacting a peripheral blood mononuclear cell in vitro with a sufficient amount of a purified B2L protein to observe a cytokine-inducing effect of the B2L protein on the peripheral blood mononuclear cell;
- and
- contacting the peripheral blood mononuclear cell with the test compound, whereby a test compound that enhances the cytokine-inducing effect of the B2L protein on the peripheral blood mononuclear cell is identified as a potential agent for enhancing the subject's immune and/or inflammatory response to B2L protein and whereby a test compound that decreases the cytokine-inducing effect of the B2L protein on the peripheral blood mononuclear cell is identified as a potential agent for inhibiting the subject's immune and/or inflammatory response to B2L protein
Dependencies are inferred from the claim text.